Reformulated Ritalin winding through approval process; Novel topical foam earns a patent;

> Highland Therapeutics reformulated version of methylphenidate (marketed as Ritalin) dosed its first patient in one of its pivotal trials. The ADHD candidate is intended for nightime dosing so that symptoms are controllable during the morning routine. More

> The feds granted Nuvo Research a patent covering novel topical foam formulations that include dimethyl sulfoxide together with certain drug actives. The technology is an important part of its topical osteoarthritis drug, dubbed Pennsaid. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.